News | March 26, 2014

Manhattan Scientifics Begins Commercial Introduction Of Nanoparticles for Use in MRI

Manhattan Scientifics Begins Commercial Introduction Of Nanoparticles for Use in MRI
March 26, 2014 – Manhattan Scientifics announced a collaboration with Azano Biotech that will make NanoMRX Precision Nanoparticles available for purchase.
 
The nanoparticles are manufactured by Senior Scientific, a division of Manhattan Scientifics, primarily to support Senior Scientific’s NanoMRX cancer detection technology. NanoMRX nanoparticles are uniquely precise and reproducible for consistent results. This is the first time they will be made available for use outside of Senior Scientific’s own programs.
 
The NanoMRX nanoparticles are manufactured to a precision not available with other iron oxide nanoparticles on the market. For discriminating researchers and precise applications, the NanoMRX nanoparticles will remove experimental variability normally associated with nanoparticles and improve results.
 
Typically, only a small portion of nanoparticle lots from existing suppliers are actually the size requested. NanoMRX particles are provided in sizes from 5 to 30 nm, with a variation of +/- 0.5 nm.
 
“We developed these high precision nanoparticles for our own cancer detection technology," said Senior Scientifics’ President Gerald Grafe. "Now we are pleased to make them available for other applications. We believe Azano is a great partner for this effort, because they already reach the community who will benefit most from the use of our precision NanoMRX nanoparticles. The market for precision nanoparticles is still in its infancy but early indications suggest a good deal of interest from a number of potential users."
 
Michael Perrine, CEO of Azano Biotech, said, “Nanoparticles are increasingly important in biomedical technologies. We are eager to make Senior Scientifics’ high precision nanoparticles available to the industry. We anticipate applications in separation, targeting, MRI contrast and Magnetic Particle Imaging (MPI).”
 
Senior Scientific, a unit of Manhattan Scientifics Inc., is pioneering the NanoMRX technology, driving it from “bench to bedside.” The technology uses non-toxic NanoMRX iron oxide nanoparticles and ultrasensitive magnetic detection for a highly sensitive and very specific approach to cancer detection that can locate and measure tumors one millionth the size detectable by X-rays and MRI.
 
For more information: www.mhtx.com

Related Content

Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI
Technology | Magnetic Resonance Imaging (MRI) | November 15, 2018
Canon Medical Systems USA Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on its new...
Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
Fans of Opposing Soccer Teams Perceive Games Differently

Image courtesy of University of York

News | Neuro Imaging | October 25, 2018
Scientists have scanned the brains of die-hard soccer fans to find out why supporters of rival teams often have very...
IMRIS, Siemens Strengthen Collaboration in Hybrid OR Neurosurgical Market
News | Hybrid OR | October 24, 2018
IMRIS, Deerfield Imaging, in partnership with Siemens Healthineers, announced a strengthened collaboration to advance...
Carotid Artery MRI Improves Cardiovascular Disease Risk Assessment
News | Magnetic Resonance Imaging (MRI) | October 23, 2018
Magnetic resonance imaging (MRI) measurements of wall thickness in the carotid arteries improve cardiovascular disease...
The Elekta Unity with 1.5T MRI embedded as a targeting system appeared at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas. The system is being sold in Europe and could soon enter the U.S. marketplace. (Photo courtesy of Elekta)

The Elekta Unity with 1.5T MRI embedded as a targeting system appeared at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas. The system is being sold in Europe and could soon enter the U.S. marketplace. (Photo courtesy of Elekta)

Feature | ASTRO | October 20, 2018 | By Greg Freiherr
A linear accelerator combined with high-field MRI could soon be on the U.S. market. If U.S.